Pseudomonas aeruginosa urinary tract infections

Pseudomonas aeruginosa Urinary tract infection An aminoglycoside Ciprofloxacin or ofloxacin... 

Since 1963 the Norwich Pharmacal Company have carried out extensive laboratory and clinical trials with l-[(5-nitrofurfurylidene)amino]imidazoli-din-2-one (NF-246, LXXV). This product is more effective in Aerobacter aerogenes, Proteus vulgaris and/or mirabilis and Pseudomonas aeruginosa urinary tract infections than nitrofurantoin (7//). ... 

Urinary tract infections Urinary tract infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca, Citrobacter sp., and Serratia marcescens. 

Levofloxacin (1), the levo-isomer or the (5)-enantiomer of ofloxacin, received FDA approval in 1996 (Fish, 2003 Hurst et al., 2002 Mascaretti, 2003 Norrby, 1999 North et al., 1998). The initial approval covered community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis, acute maxillary sinusitis, uncomplicated skin and skin structure infections, acute pyelonephritis, and complicated urinary tract infections (North et al., 1998). Four years later, the levofloxacin indication list grew to include community-acquired pneumonia caused by penicillin-resistant Streptococcus pneumoniae. In addition, in 2002, nosocomial (hospital-acquired) pneumonia caused by methicillin-susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Haemophilus influenzae, Kliebsella pneumoniae, and Escherichia coli was added (Hurst et al., 2002). Finally in 2004, LVX was approved as a post-exposure treatment for individuals exposed to Bacillus anthracis, the microbe that causes anthrax, via inhalation (FDA, 2004). 

L B. The patient has complicated urinary tract infection and nonsevere sepsis syndrome caused by P. aeruginosa. Effective antibiotics for Pseudomonas spp. include mezlocillin, piperacillin, piperacillin-tazobactam, ticarcillin, and ticarciUin-clavulanate. The carbapenems (imipenem and meropenem) and the monobactam (aztreonam) are also active against P. aeruginosa. Ampicillin-sulbactam and cefazolin are ineffective against P. 

The fluoroquinolones represent an important therapeutic advance and are extremely useful agents. They are important for the treatment of Gram-negative urinary tract infections, especially those from sulfa-resistant strains of E. coli, and for the treatment of serious hacterial infections such as those caused by Pseudomonas aeruginosa. On the basis of microbiological considerations, the fluoroquinolones may be further subdivided into three groups ... 

Urinary Tract Infections Pseudomonas aeruginosa Killed 5 ppm... 

B. Carbenicillin Urinary tract infection caused by Pseudomonas aeruginosa (p-lactamase negative)... 

Two types of gram-negative rods cause eye infections. Haemophilus influenzae causes infections in early childhood, with otitis media and conjimctivitis often seen concurrently. The enteric gram-negative rods include Escherichia coli, Serratia marcescens, Proteus, and Pseudomonas aeruginosa. These bacteria are typically found in the intestinal tract and commonly cause urinary tract infections. In the eye they can cause corneal ulcers. 

Sulfonamides stop the growth of E. coli and Pseudomonas aeruginosa, Serratia, Enterobacter. Sulfonamides are prescribed for urinary tract infections. 

Lomefloxacin, a fluoroquinolone broad-spectrum antibiotic (400 mg p.o. daily for 10 to 14 days), is used in acute bacterial exacerbations of chronic bronchitis caused by Haemophilis influenzae or Moraxella (Branhamella) catarrhalis in uncomphcated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Staphylococcus saprophyticus, in complicated urinary tract infections caused by E. coli, K. pneumoniae, P. mirabilis, and Pseudomonas aeruginosa and it is possibly effective against infections caused by Citrobacter diversus or Enterobacter cloacae and for the prophylaxis of infections after transurethral surgical procedures (see also Figure 85). 

Items 75-76. A 36-year-old patient is hospitalized following injuries sustained in an automobile accident. After several days, he develops a urinary tract infection due to Pseudomonas aeruginosa. 

Urinary tract infections (UTI) are the most commonly reported bacterial infection in the United State. E coli causes 90% of them, some of which are hospital acquired. Hospital acquired UTI are difficult to treat. Other UTI are caused by Pseudomonas aeruginosa, Serratia, and Enterobacter... 

For urinary tract infections juniper, uva ursi (Arctostaphylos uva-ursi), eucalyptus, goldenseal, cranberry. Cassia Fistula and five other Cassia species have been found effective in vitro against Pseudomonas aeruginosa. C. Fistula is excreted in the urine and thus should be good for UTI. 

Kurosaka, Y., Ishida, Y., Yamamura, E Takase, H Otani, T., and Kumon, H. (2001) A non-surgical rat model of foreign body-associated urinary tract infection with Pseudomonas aeruginosa. Microbiol. Immunol. 45, 9-15. 

These agents generally have been replaced by more agents due to resistance. This combination is highly effective against most aerobic enteric bacteria except Pseudomonas aeruginosa. High urinary tract tissue levels and urine levels are achieved, which may be important in complicated infection treatment. Also effective as prophylaxis for recurrent infections,... 

---